Biogen (BIIB) Tops Q3 EPS by 66c, Updates FY Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/21/2026
- Wall St indexes advance with boost from chips, Iran optimism
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- SanDisk and Micron surge as Apple confirms memory price pass-through
- Zelenskiy: best guarantee of Europe's future is fast-track EU membership for Ukraine
- Needham Starts NeoVolta (NEOV) at Buy
- Fed: Nine Of 18 FOMC Participants Pencil In 2026 Rate Hike
- Delta Air Lines (DAL) Raises Quarterly Dividend 14.7% to $0.2150; 1% Yield
- Oil rises 1% on US-Iran deal doubts; IEA warns of supply glut
Biogen (BIIB) Stock Edges Higher on Strong Earnings, Sales of New Alzheimer Drug Just $300k
October 20, 2021 9:00 AM EDTBiogen (NASDAQ: BIIB) stock is up about 1.5% in pre-open Wednesday after the company reported better-than-expected Q3 EPS.
BIIB reported Q3 EPS of $4.77 to beat the analyst estimate of $4.11. Revenue for the quarter came in at $2.78 million versus the consensus estimate of $2.67 million.
As far as full-year guidance is concerned, Biogen projects FY2021 EPS of $18.85-$19.35, versus the consensus of $18.61.... More
Long-term Prospects for Biogen’s (BIIB) Aduhelm Remain Key Question - Analyst
October 20, 2021 8:21 AM EDTEarlier today, Biogen (NASDAQ: BIIB) reported Q3 results: EPS of $4.77, $0.66 better than the analyst estimate of $4.11; revenue for the quarter came in at $2.78 million versus the consensus estimate of $2.67 million.
The company also updated its full-year guidance: EPS of $18.85-$19.35, versus the consensus of $18.61; FY2021... More
